AbCellera Biologics Inc. · NASDAQ
No direct coverage yet · Showing articles that mention ABCL
Zacks Investment Research
Nurix Therapeutics, Inc. (NRIX) Q3 Earnings and Revenues Surpass EstimatesNurix Therapeutics reported Q3 2026 earnings of $4.73 per share, significantly beating the consensus estimate of a loss of $0.56 per share, with a 944.64% earnings surprise. Revenues reached $673.06 million, surpassing estimates by 383.11%. However, the stock received a Zacks Rank #3 (Hold) rating, with mixed estimate revisions and the company's industry ranking in the bottom 33% of sectors.
GlobeNewswire Inc.
Global Synthetic Antibody Library Market Report 2026: Size and Forecast to 2030 | Capitalize on 12% CAGR and AI Design with Charles River, Twist Bioscience, GenScript and AbCelleraThe global synthetic antibody library market is projected to grow from $1.63 billion in 2025 to $2.86 billion by 2030, representing a 12% CAGR. Growth is driven by AI-integrated antibody design, increased demand for therapeutic antibodies, high-throughput screening technologies, and expansion of contract research organizations. North America leads the market while Asia-Pacific shows fastest growth potential.
Headlines link to the publisher. Not investment advice.
Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.
No sentiment yet
Sign in to post on $ABCL
No threads yet
Community posts are member opinions. Desk posts are automated weekly counts. Not investment advice.
